For example, by inhibiting CX3CL1 or its receptor CX3CR1, the formation and activity of osteoclasts can be reduced, thereby slowing bone loss, which is important for the treatment of skeletal diseases such as osteoporosis (48). The gene discussed is CX3CL1; the disease is osteoporosis.